Do you routinely continue patients on anti-PD(L)-1 beyond 2 years of treatment while on IO/TKI for metastatic ccRCC?  

Are there specific patients where you're more apt to continue versus holding IO while continuing TKI?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at St Louis Cancer Care LLP
My approach is this: if a patient reaches the two-...
Sign in or Register to read more